DK200401402A
|
|
New 1,4-naphthoquinone derivs. - used for treatment and prophylaxis of Pneumocystis carinii infections and malaria
|
US2002164788A1
|
|
Humanized antibodies to CD38
|
CZ82099A3
|
|
Method of determining purity and stability of lanotrigin sample
|
HK1003055A1
|
|
Guanine derivative
|
CZ286719B6
|
|
Tablets dispersible in water and containing lamotrigin
|
FI970666A0
|
|
Enantiomeric intermediates
|
CN1162643A
|
|
Preparation and usage of molecular chimera for curing cancer
|
US5679694A
|
|
Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents
|
LV5762A4
|
|
Naftoquinone Derivatives
|
LV5758A4
|
|
Contains active ingredient for controlled delivery
|
FI961410A
|
|
Pharmacologically active compounds with action on the central nervous system
|
MY115461A
|
|
Synergistic combinations of zidovudine, 1592u89 and 3tc
|
CA2215748A1
|
|
Freeze-drying process and apparatus
|
GB9603522D0
|
|
Chemical process
|
GB9603256D0
|
|
Antibodies
|
GB9600143D0
|
|
Therapeutic compounds
|
GB9600142D0
|
|
Chemical compounds
|
GB9525105D0
|
|
New compound
|
GB9523714D0
|
|
Enzyme prodrug therapy
|
GB9523715D0
|
|
Hybrid nucleotide
|